Injectafer

Ferric carboxymaltose, the active ingredient in Injectafer, is an iron supplement presented as an injection solution for intravenous infusion use. It treats iron deficiency anemia in adults with chronic kidney disease, inflammatory bowel disease, postpartum hemorrhage, or those intolerant to oral iron therapy.

GNH USA supplies Injectafer as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Injectafer (ferric carboxymaltose) is used to correct iron deficiency anemia in adult patients where oral iron is ineffective or contraindicated.

- Chronic kidney disease: restores hemoglobin levels and replenishes iron stores in adults with CKD‑related anemia. - Inflammatory bowel disease: improves anemia by providing intravenous iron when gastrointestinal absorption is impaired. - Postpartum hemorrhage: rapidly corrects iron loss after significant postpartum bleeding. - Oral iron intolerance: offers an alternative for patients who cannot tolerate oral iron preparations.

Injectafer may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal discomfort. - Headache: transient cranial pain. - Injection site pain: local discomfort or erythema. - Hypotension: temporary drop in blood pressure during infusion.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Hypophosphatemia: marked decrease in serum phosphate levels. - Acute liver injury: elevated liver enzymes indicating hepatic stress. - Cardiovascular events: arrhythmias or myocardial ischemia in susceptible patients.

Before administering Injectafer, several safety considerations should be observed. - Assess iron status: confirm iron deficiency anemia and evaluate ferritin and TSAT levels. - Monitor during infusion: observe vital signs for hypotension or hypersensitivity. - Review cardiac history: patients with known cardiac disease may need closer monitoring. - Check renal function: adjust monitoring in severe renal impairment. - Avoid in known hypersensitivity: contraindicated in patients with previous severe reactions to ferric carboxymaltose or its components. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Injectafer can interact with certain medicines, influencing its safety or efficacy.

Major Interactions (Avoid): - Concurrent use of other IV iron products: may cause iron overload. - High-dose vitamin C supplements: increase iron absorption and risk of oxidative stress.

Moderate Interactions (Monitor Closely): - Erythropoiesis‑stimulating agents: may augment hemoglobin rise, requiring dose adjustment. - Antacids containing aluminum or magnesium: can affect iron complex stability. - Certain antibiotics (e.g., tetracyclines, fluoroquinolones): may chelate iron and reduce antibiotic effectiveness.